Gastric Neuroendocrine Tumor Market – Global Industry Size, Trends & Forecast to 2034
Roshan Kumar
Gastric Neuroendocrine Tumor Market Overview
The gastric neuroendocrine tumor (GNET) market has witnessed significant growth in recent years, driven by increasing awareness of the condition, advancements in treatment options, and ongoing clinical trials. GNETs are rare tumors that arise from the neuroendocrine cells in the stomach and can be either malignant or benign. The management of GNETs includes surgery, chemotherapy, immunotherapy, and radiation therapy, among others, which have been improving due to continuous research and development efforts. As the number of diagnosed cases increases, the demand for effective treatments has surged, leading to a growing market opportunity. In 2024, the global market for gastric neuroendocrine tumors was valued at USD 1.85 billion, with a forecasted growth rate of 3.34% CAGR during the 2025-2034 period.
Gastric Neuroendocrine Tumor Market Size and Share
The gastric neuroendocrine tumor market is currently valued at USD 1.85 billion in 2024, and this figure is expected to reach USD 2.57 billion by 2034, growing at a CAGR of 3.34%. This growth can be attributed to the increasing incidence of gastric cancer, a supportive regulatory environment, and an expanding pool of clinical trials that are exploring novel therapeutic options. The major contributors to this market include advancements in the diagnostic processes and improved treatment regimens, with strong demand for innovative therapeutics in developed and emerging markets alike. Check out Expert Market Research's gastric neuroendocrine tumor market report for more insights into emerging sectors.
Gastric Neuroendocrine Tumor Market Trends
-
Growing Prevalence of Gastric Cancer
The increasing global incidence of gastric cancer has significantly influenced the growth of the gastric neuroendocrine tumor market. As gastric cancer becomes more prevalent, the awareness of neuroendocrine tumors is also increasing. Medical professionals are becoming more attuned to identifying and treating these rare tumors early, which, in turn, is boosting the market demand for specialized treatment options. Early-stage diagnosis and enhanced surveillance techniques are also contributing to the growing market. -
Advances in Diagnostic Techniques
Technological advancements in diagnostic procedures, such as the use of endoscopic ultrasound and positron emission tomography (PET) scans, are helping healthcare providers diagnose gastric neuroendocrine tumors with greater precision. As the accuracy of diagnosis improves, the ability to offer timely interventions is enhancing, thus contributing to better patient outcomes and, ultimately, higher demand for treatment options. This trend is expected to continue, further fueling market growth.
-
Increasing Focus on Targeted Therapies
One of the most notable trends in the gastric neuroendocrine tumor market is the growing emphasis on targeted therapies. These therapies aim to specifically target cancer cells while minimizing damage to surrounding healthy tissues. Targeted therapies such as somatostatin analogs and tyrosine kinase inhibitors are proving to be highly effective in treating GNETs. The continued research and development in this area are expected to lead to a broader range of treatment options, boosting market growth. -
Rising Clinical Trials and Drug Development
An increase in clinical trials focusing on novel therapies for gastric neuroendocrine tumors has been one of the key drivers for market growth. Pharmaceutical companies and research organizations are actively pursuing the development of new drugs that offer improved outcomes for patients with GNETs. With regulatory agencies offering supportive frameworks for drug approval, the influx of novel therapeutics is expected to shape the future landscape of the market, offering new treatment alternatives for patients.
Gastric Neuroendocrine Tumor Market Analysis
-
Treatment Type
The market for gastric neuroendocrine tumor treatment is divided into several segments, with chemotherapy, immunotherapy, surgery, and radiation therapy being the primary treatment options. Surgery remains the most common treatment, especially for early-stage tumors, while chemotherapy and immunotherapy are used for advanced-stage or metastatic GNETs. As new targeted therapies are introduced, these treatments are expected to gain market share and drive growth. -
Route of Administration
The route of administration for gastric neuroendocrine tumor therapies can be classified into oral, parenteral, and others. Oral administration, particularly for chemotherapy and targeted therapy drugs, is becoming increasingly preferred due to convenience and ease of use. However, parenteral drugs, which are administered through injections, remain critical for more aggressive treatments, including chemotherapy and immunotherapy. The continued development of oral therapies could lead to an increase in market share for this route. -
End User
Hospitals, clinics, diagnostic centers, research laboratories, and other healthcare settings are the primary end users of GNET treatments. Hospitals hold the largest share of the market, as they are equipped with the necessary infrastructure to treat patients with advanced stages of the disease. The increasing availability of specialized diagnostic tools and surgical procedures in diagnostic centers and clinics is also contributing to the growth of these end-user segments. -
Regional Insights
The gastric neuroendocrine tumor market is expanding globally, with significant contributions from North America, Europe, and Asia-Pacific. In particular, the United States is a major player due to the high prevalence of gastric cancer and advanced healthcare infrastructure. Meanwhile, regions like Japan and India are also seeing increased market activity due to improvements in healthcare access and treatment options, along with rising patient awareness and better diagnostic capabilities.
Get Ahead of the Curve in the Gastric Neuroendocrine Tumor Market!
Uncover valuable market intelligence, global projections, and actionable data—a free report is available now.
Gastric Neuroendocrine Tumor Scope of the Report
This report provides an in-depth analysis of the gastric neuroendocrine tumor market, including a detailed overview of historical and forecast trends, industry drivers and constraints, and market segmentation. The report also covers a breakdown of market trends based on treatment types, routes of administration, and end-user categories, as well as regional insights from the major global markets.
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment
Treatment Type
-
Chemotherapy: Chemotherapy remains a cornerstone of GNET treatment, particularly for metastatic tumors. Drugs like temozolomide and streptozocin are commonly used, and their effectiveness in controlling tumor growth is widely acknowledged.
-
Immunotherapy: Immunotherapy is emerging as a promising treatment option for GNETs, particularly in cases resistant to conventional chemotherapy. Drugs like pembrolizumab are gaining attention for their potential in treating neuroendocrine tumors.
-
Surgery: Surgical removal of tumors is the most effective treatment option for early-stage GNETs. Advances in minimally invasive surgery have further improved patient outcomes.
-
Radiation Therapy: Radiation therapy is often used in conjunction with surgery and chemotherapy to target any remaining tumor cells. It is especially useful for palliative care in advanced cases.
-
Others: New treatments, such as targeted therapies and combination therapies, are under development and are expected to contribute significantly to market growth in the future.
Route of Administration
-
Oral: Oral drugs are more convenient for patients, leading to their increasing popularity, particularly in less aggressive cases of GNETs.
-
Parenteral: Injectable drugs remain essential for aggressive treatments, including chemotherapy and immunotherapy.
-
Others: This category includes subcutaneous and intramuscular injections, as well as the use of novel drug delivery systems.
End User
-
Hospitals: Hospitals remain the primary setting for GNET treatment, especially for surgical interventions and advanced therapies.
-
Clinics: Clinics are becoming increasingly important for diagnostic procedures and routine monitoring.
-
Diagnostic Centers: Diagnostic centers play a critical role in early detection and staging of GNETs.
-
Research Laboratories: Research laboratories continue to drive innovation, with numerous ongoing clinical trials focused on developing new therapies for GNETs.
Gastric Neuroendocrine Tumor Regional Insights
-
United States:
The U.S. is a key market for gastric neuroendocrine tumors, driven by a high incidence of gastric cancer and neuroendocrine tumors. The country's advanced healthcare infrastructure, combined with substantial government and private sector investment in cancer research, positions it as a leader in the development and adoption of innovative GNET therapies. -
EU-4 and the United Kingdom:
Europe, particularly the EU-4 (Germany, France, Italy, and Spain) and the United Kingdom, is witnessing steady growth in the gastric neuroendocrine tumor market. The region benefits from strong healthcare systems, increased awareness, and rising investments in clinical trials, which are expected to drive market growth. -
Japan:
Japan has a highly developed healthcare system, and it is one of the major contributors to the GNET market in Asia. The increasing prevalence of gastric cancer and the rising adoption of innovative treatments are helping drive the market. -
India:
India’s growing healthcare infrastructure and increasing access to advanced medical technologies are driving the gastric neuroendocrine tumor market. As awareness of GNETs rises, more patients are seeking treatment, contributing to market expansion.
Gastric Neuroendocrine Tumor Market Growth
The primary factors driving the growth of the gastric neuroendocrine tumor market include advancements in diagnostic techniques, the increasing prevalence of gastric cancer, and the development of novel therapies. Clinical trials and research are pushing the boundaries of treatment options, while regulatory support for drug approval is fostering innovation. As new drugs and therapies enter the market, opportunities for growth will expand, particularly in emerging markets with growing healthcare access.
Recent Developments & Challenges
-
Regulatory Approvals: New drugs like capecitabine and temozolomide are gaining regulatory approval, enhancing the range of treatment options available for patients.
-
Industry Innovation: Targeted therapies and immunotherapies are becoming increasingly popular due to their effectiveness in treating advanced-stage tumors.
-
Challenges in Diagnosis: GNETs are often diagnosed at a late stage due to their rarity, which can delay treatment and reduce patient survival rates.
-
High Treatment Costs: The cost of novel treatments can be prohibitive for patients in developing countries, limiting market accessibility.
Gastric Neuroendocrine Tumor Key Players
Novartis AG: Novartis is a leader in the development of innovative therapies for GNETs. Their focus on immunotherapies and targeted therapies positions them at the forefront of the market. The company’s efforts in expanding its oncology portfolio are significant for GNET treatment innovation.
Pfizer Inc.: Pfizer is a global pharmaceutical leader with a strong presence in the oncology sector. The company’s research into targeted therapies and its collaboration with research institutions play a critical role in advancing GNET treatment options.
Boehringer Ingelheim International GmbH: Boehringer Ingelheim is developing cutting-edge therapies for gastric neuroendocrine tumors. Their focus on molecular therapies and immunotherapy is expected to provide new options for patients.
Eli Lilly and Company: Eli Lilly’s contributions to the GNET market are primarily in the form of targeted therapies and chemotherapy options. Their ongoing research and commitment to oncology are vital to the continued growth of the market.
Other key players in the market include F-Hoffmann-La Roche Ltd, Merck & Co., and AstraZeneca.
FAQs
-
What is a gastric neuroendocrine tumor?
A gastric neuroendocrine tumor (GNET) is a rare type of cancer that develops from the neuroendocrine cells in the stomach. It can be benign or malignant and requires specific treatment approaches. -
How is GNET treated?
Treatment options for GNET include surgery, chemotherapy, immunotherapy, and radiation therapy, depending on the stage and aggressiveness of the tumor. -
What are the leading treatment options for GNETs?
Chemotherapy, immunotherapy, and targeted therapies are the primary treatment options. Surgery is often used in early-stage cases. -
Which regions are seeing the highest growth in the GNET market?
The United States, Europe, Japan, and India are among the leading regions for the GNET market, driven by rising awareness, advanced healthcare systems, and increasing incidence of gastric cancer.
Check Out More Reports
About Us:
Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.
Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.
Media Contact:
Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: [email protected]
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com
